Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote

Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent
FDA Advisory Committee Vote

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today plans to reduce operating expenses by eliminating
approximately fifty percent of its staff positions worldwide following the
recent recommendation of the U.S. Food and Drug Administration (FDA)
Endocrinologic and Metabolic Drugs Advisory Committee against the potential
Vascepa^® (icosapent ethyl) label expansion.

Amarin will continue its dialogue with FDA regarding the ANCHOR data. Given
the outcome of the advisory committee meeting, Amarin feels this shift in
staffing is the appropriate corporate action.Amarin is grateful to all
employees for their significant efforts and contributions to the organization.

As part of the reduction in staffing the company will retain approximately
half of its highest performing sales professionals in targeted geographical
areas and pursue continued prescription growth of Vascepa in the current
approved indication.This optimized team will cover the target base of
physicians responsible for the vast majority of Vascepa prescription volume
and growth since its launch in early 2013.With this optimization and
resulting target base coverage, Amarin anticipates continued Vascepa revenue
growth over time.

As of September 30, 2013, Amarin had cash, cash equivalents
ofapproximately$226million.Amarin anticipates approximately $3 million in
restructuring expense in association with this reduction in staffing.The
company currently expects its cash burn for 2014 to be less than $80
million.The company has no plans for raising additional capital at this
time.Amarin intends to continue its evaluation of priorities, opportunities
and savings opportunities, including clinical trial costs. The company plans
to provide additional details of its future spending and operational
expectations in connection with its upcoming quarterly report.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit For more information about Amarin visit

Forward-looking statements

This press release contains forward-looking statements, including statements
about Amarin's pending ANCHOR Supplemental New Drug Application, anticipated
sales force size and projected ability of its sales force to cover targeted
physicians and grow revenues, anticipated payroll, restructuring and operating
expenses, expectations for cash burn in 2014 and the company's current plan
not to raise additional capital. These forward-looking statements are not
promises or guarantees and involve substantial risks and uncertainties. In
particular, the expenses associated with the reduction in force may be higher
than expected due to litigation or otherwise and Amarin may not realize in
full the expected benefit in reduced operating expenses.In addition, as a
result in the reduction in force, which primarily affects Amarin's sales
force, and the outcome of the Endocrinologic and Metabolic Drug Advisory
Committee meeting recommending against Vascepa label expansion, Amarin's
ability to maintain and grow revenue from sales of Vascepa in the current
indication may be materially adversely affected. Among the factors that could
cause actual results to differ materially from those described or projected
herein include the following: uncertainties associated generally with FDA
decisions and specifically information presented at the recent Endocrinologic
and Metabolic Drug Advisory Committee meeting, retention of employees,
predicting future sales, sales operations and operating expenses. A further
list and description of these risks, uncertainties and other risks associated
with an investment in Amarin can be found in Amarin's filings with the U.S.
Securities and Exchange Commission, including its most recent Quarterly Report
on Form 10-Q. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date hereof. Amarin undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (, our investor
relations website (, including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315

company logo
Press spacebar to pause and continue. Press esc to stop.